Best percentage change from baseline in 23 patients with evaluable measurements. This plot excludes 5 unevaluable patients and 1 patient with pancreatic adenocarcinoma who was classified as having progressive disease but for whom complete data for target lesions were not available. (*) New lesions. Adeno, adenocarcinoma; ca, carcinoma; GYN, gynecologic; intra cholangia, intrahepatic cholangiocarcinoma; PD, progressive disease; PR, partial response; SD, stable disease.